Click for best price
Postpemic Era Squamous NonSmall Cell Lung Cancer Therapeutics Market Size, Share 2022
Summary
The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.
2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.
According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.
Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Segment Research Report 2022?, which aims to sort out the development status and trends of the Squamous Non-Small Cell Lung Cancer Therapeutics industry at home and abroad, estimate the overall market scale of the Squamous Non-Small Cell Lung Cancer Therapeutics industry and the market share of major countries, Squamous Non-Small Cell Lung Cancer Therapeutics industry, and study and judge the downstream market demand of Squamous Non-Small Cell Lung Cancer Therapeutics through systematic research, Analyze the competition pattern of Squamous Non-Small Cell Lung Cancer Therapeutics, so as to help solve the pain points of various stakeholders in Squamous Non-Small Cell Lung Cancer Therapeutics industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.
Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Squamous Non-Small Cell Lung Cancer Therapeutics Market by XYZResearch Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Squamous Non-Small Cell Lung Cancer Therapeutics Market?
Ascenta Therapeutics, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Bayer AG
BIND Therapeutics, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Genentech, Inc.
Incyte Corporation
Johnson & Johnson
MacroGenics, Inc.
Novartis AG
Oncogenex Pharmaceuticals, Inc.
PsiOxus Therapeutics Limited
Major Type of Squamous Non-Small Cell Lung Cancer Therapeutics Covered in XYZResearch report:
BMS-906024
Buparlisib Hydrochloride
FP-1039
Ipilimumab
JNJ-42756493
Lenvatinib
Others
Application Segments Covered in XYZResearch Market
Research Center
Hospital
Clinic
For any other requirements, please feel free to contact us and we will provide you customized report.
| Report Attributes |
Report Details |
| Report Title |
(Post-pandemic Era)-Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Segment Research Report 2022 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
111 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
Table of Contents
Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market by Value
2.2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type
2.2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market by Value (%)
2.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market by Production
2.3.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Production by Type
2.3.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market by Production (%)
3. The Major Driver of Squamous Non-Small Cell Lung Cancer Therapeutics Industry
3.1 Historical & Forecast Global Squamous Non-Small Cell Lung Cancer Therapeutics Demand
3.2 Largest Application for Squamous Non-Small Cell Lung Cancer Therapeutics (2018-2028)
3.3 The Major Downstream Company in China Market 2022
4. Global and Regional Squamous Non-Small Cell Lung Cancer Therapeutics Market
4.1 Regional Market Size in Terms of Production & Demand (2022)
4.2 Regional Market Share in Terms of Revenue (2018-2022)
4.3 Concentration Ratio (CR5& CR10) of Squamous Non-Small Cell Lung Cancer Therapeutics Market
4.4 Mergers & Acquisitions, Expansion Plans
5. US Squamous Non-Small Cell Lung Cancer Therapeutics Production, Demand (2018-2028)
5.1 Current and Estimated Production Breakdown by Type
5.2 Current and Estimated Demand Breakdown by Type
5.3 Current and Estimated Demand Breakdown by Application
5.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
6. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Production, Demand (2018-2028)
6.1 Current and Estimated Production Breakdown by Type
6.2 Current and Estimated Demand Breakdown by Type
6.3 Current and Estimated Demand Breakdown by Application
6.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
7. China Squamous Non-Small Cell Lung Cancer Therapeutics Production, Demand (2018-2028)
7.1 Current and Estimated Production Breakdown by Type
7.2 Current and Estimated Demand Breakdown by Type
7.3 Current and Estimated Demand Breakdown by Application
7.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
8. Japan Squamous Non-Small Cell Lung Cancer Therapeutics Production, Demand (2018-2028)
8.1 Current and Estimated Production Breakdown by Type
8.2 Current and Estimated Demand Breakdown by Type
8.3 Current and Estimated Demand Breakdown by Application
8.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
9. India Squamous Non-Small Cell Lung Cancer Therapeutics Production, Demand (2018-2028)
9.1 Current and Estimated Production Breakdown by Type
9.2 Current and Estimated Demand Breakdown by Type
9.3 Current and Estimated Demand Breakdown by Application
9.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
10. Korea Squamous Non-Small Cell Lung Cancer Therapeutics Production, Demand (2018-2028)
10.1 Current and Estimated Production Breakdown by Type
10.2 Current and Estimated Demand Breakdown by Type
10.3 Current and Estimated Demand Breakdown by Application
10.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
11. Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Production, Demand (2018-2028)
11.1 Current and Estimated Production Breakdown by Type
11.2 Current and Estimated Demand Breakdown by Type
11.3 Current and Estimated Demand Breakdown by Application
11.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
12. Global Squamous Non-Small Cell Lung Cancer Therapeutics Average Price Trend
12.1 Market Price for Each Type of Squamous Non-Small Cell Lung Cancer Therapeutics in US (2018-2022)
12.2 Market Price for Each Type of Squamous Non-Small Cell Lung Cancer Therapeutics in Europe (2018-2022)
12.3 Market Price for Each Type of Squamous Non-Small Cell Lung Cancer Therapeutics in China (2018-2022)
12.4 Market Price for Each Type of Squamous Non-Small Cell Lung Cancer Therapeutics in Japan (2018-2022)
12.5 Market Price for Each Type of Squamous Non-Small Cell Lung Cancer Therapeutics in India (2018-2022)
12.6 Market Price for Each Type of Squamous Non-Small Cell Lung Cancer Therapeutics in Korea (2018-2022)
12.7 Market Price for Each Type of Squamous Non-Small Cell Lung Cancer Therapeutics in Southeast Asia (2018-2022)
13. Industrial Chain (Impact of COVID-19)
13.1 Squamous Non-Small Cell Lung Cancer Therapeutics Industrial Chain Analysis
13.2 Downstream
13.3 Impact of COVID-19
13.4 Post-pandemic Era
13.5 Technology Trends of Squamous Non-Small Cell Lung Cancer Therapeutics
14. Squamous Non-Small Cell Lung Cancer Therapeutics Competitive Landscape
14.1 Ascenta Therapeutics, Inc.
14.1.1 Ascenta Therapeutics, Inc. Company Profiles
14.1.2 Ascenta Therapeutics, Inc. Product Introduction
14.1.3 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Sales, Revenue (2018-2022)
14.1.4 Strategic initiatives
14.2 AstraZeneca Plc
14.2.1 AstraZeneca Plc Company Profiles
14.2.2 AstraZeneca Plc Product Introduction
14.2.3 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Sales, Revenue (2018-2022)
14.2.4 Strategic initiatives
14.3 AVEO Pharmaceuticals, Inc.
14.3.1 AVEO Pharmaceuticals, Inc. Company Profiles
14.3.2 AVEO Pharmaceuticals, Inc. Product Introduction
14.3.3 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Sales, Revenue (2018-2022)
14.3.4 Strategic initiatives
14.4 Bayer AG
14.4.1 Bayer AG Company Profiles
14.4.2 Bayer AG Product Introduction
14.4.3 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Sales, Revenue (2018-2022)
14.4.4 Strategic initiatives
14.5 BIND Therapeutics, Inc.
14.5.1 BIND Therapeutics, Inc. Company Profiles
14.5.2 BIND Therapeutics, Inc. Product Introduction
14.5.3 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Sales, Revenue (2018-2022)
14.5.4 Strategic initiatives
14.6 Boehringer Ingelheim GmbH
14.6.1 Boehringer Ingelheim GmbH Company Profiles
14.6.2 Boehringer Ingelheim GmbH Product Introduction
14.6.3 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Sales, Revenue (2018-2022)
14.6.4 Strategic initiatives
14.7 Bristol-Myers Squibb Company
14.7.1 Bristol-Myers Squibb Company Company Profiles
14.7.2 Bristol-Myers Squibb Company Product Introduction
14.7.3 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Sales, Revenue (2018-2022)
14.7.4 Strategic initiatives
14.8 Eli Lilly and Company
14.8.1 Eli Lilly and Company Company Profiles
14.8.2 Eli Lilly and Company Product Introduction
14.8.3 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Sales, Revenue (2018-2022)
14.8.4 Strategic initiatives
14.9 F. Hoffmann-La Roche Ltd.
14.9.1 F. Hoffmann-La Roche Ltd. Company Profiles
14.9.2 F. Hoffmann-La Roche Ltd. Product Introduction
14.9.3 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Sales, Revenue (2018-2022)
14.9.4 Strategic initiatives
14.10 Five Prime Therapeutics, Inc.
14.10.1 Five Prime Therapeutics, Inc. Company Profiles
14.10.2 Five Prime Therapeutics, Inc. Product Introduction
14.10.3 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Sales, Revenue (2018-2022)
14.10.4 Strategic initiatives
14.11 Genentech, Inc.
14.12 Incyte Corporation
14.13 Johnson & Johnson
14.14 MacroGenics, Inc.
14.15 Novartis AG
14.16 Oncogenex Pharmaceuticals, Inc.
14.17 PsiOxus Therapeutics Limited
15. Conclusion
16. Methodology and Data Source
LIST OF TABLES & FIGURES
List of Tables and Figures
Figure 1. Total Demand by Application of Squamous Non-Small Cell Lung Cancer Therapeutics Industry (Volume)
Figure 2. Squamous Non-Small Cell Lung Cancer Therapeutics Production & Demand by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2027)
Figure 4. The Top 10 and 5 Players Market Share by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in 2022
Figure 5. US Squamous Non-Small Cell Lung Cancer Therapeutics Production, Demand (2018-2028)
Figure 6. Production Breakdown by Type (%)
Figure 7. Demand Breakdown by Type (%)
Figure 8. Demand Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Production, Demand (2018-2028)
Figure 12. Production Breakdown by Type (%)
Figure 13. Demand Breakdown by Type (%)
Figure 14. Demand Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Squamous Non-Small Cell Lung Cancer Therapeutics Production, Demand (2018-2028)
Figure 18. Production Breakdown by Type (%)
Figure 19. Demand Breakdown by Type (%)
Figure 20. Demand Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Squamous Non-Small Cell Lung Cancer Therapeutics Production, Demand (2018-2028)
Figure 25. Production Breakdown by Type (%)
Figure 26. Demand Breakdown by Type (%)
Figure 27. Demand Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Squamous Non-Small Cell Lung Cancer Therapeutics Production, Demand (2018-2028)
Figure 31. Production Breakdown by Type (%)
Figure 32. Demand Breakdown by Type (%)
Figure 33. Demand Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Squamous Non-Small Cell Lung Cancer Therapeutics Production, Demand (2018-2028)
Figure 37. Production Breakdown by Type (%)
Figure 38. Demand Breakdown by Type (%)
Figure 39. Demand Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Production, Demand (2018-2028)
Figure 43. Current and Estimated Production Breakdown by Type (2018-2028)
Figure 44. Production Breakdown by Type (%)
Figure 45. Demand Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, by Type (Million USD) (2018-2028)
Table 4. Squamous Non-Small Cell Lung Cancer Therapeutics Production, by Type (K Unit) (2018-2028)
Table 5. Squamous Non-Small Cell Lung Cancer Therapeutics Demand (K Unit) by Application (2018-2028)
Table 6. Squamous Non-Small Cell Lung Cancer Therapeutics Demand (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Production & Demand (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2027)
Table 10. Ranking of Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Squamous Non-Small Cell Lung Cancer Therapeutics Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 13. Current and Estimated Production Breakdown by Type (2018-2028)
Table 14. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 15. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 19. Current and Estimated Production Breakdown by Type (2018-2028)
Table 20. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 21. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Squamous Non-Small Cell Lung Cancer Therapeutics Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 25. Table Current and Estimated Production Breakdown by Type
Table 26. Current and Estimated Demand Breakdown by Type
Table 27. Current and Estimated Demand Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Squamous Non-Small Cell Lung Cancer Therapeutics Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 30. Current and Estimated Production Breakdown by Type (2018-2028)
Table 31. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 32. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Squamous Non-Small Cell Lung Cancer Therapeutics Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 36. Current and Estimated Production Breakdown by Type (2018-2028)
Table 37. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 38. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Squamous Non-Small Cell Lung Cancer Therapeutics Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 42. Current and Estimated Production Breakdown by Type (2018-2028)
Table 43. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 44. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 48. Table Current and Estimated Demand Breakdown by Type (2018-2028)
Table 49. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Squamous Non-Small Cell Lung Cancer Therapeutics in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Squamous Non-Small Cell Lung Cancer Therapeutics in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Squamous Non-Small Cell Lung Cancer Therapeutics in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Squamous Non-Small Cell Lung Cancer Therapeutics in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Squamous Non-Small Cell Lung Cancer Therapeutics in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Squamous Non-Small Cell Lung Cancer Therapeutics in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Squamous Non-Small Cell Lung Cancer Therapeutics in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Ascenta Therapeutics, Inc. Profiles
Table 61. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
Table 62. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 63. Ascenta Therapeutics, Inc. Strategic initiatives
Table 64. AstraZeneca Plc Profiles
Table 65. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
Table 66. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 67. AstraZeneca Plc Strategic initiatives
Table 68. AVEO Pharmaceuticals, Inc. Profiles
Table 69. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
Table 70. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 71. AVEO Pharmaceuticals, Inc. Strategic initiatives
Table 72. Bayer AG Profiles
Table 73. Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
Table 74. Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 75. Bayer AG Strategic initiatives
Table 76. BIND Therapeutics, Inc. Profiles
Table 77. BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
Table 78. BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 79. BIND Therapeutics, Inc. Strategic initiatives
Table 80. Boehringer Ingelheim GmbH Profiles
Table 81. Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
Table 82. Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 83. Boehringer Ingelheim GmbH Strategic initiatives
Table 84. Bristol-Myers Squibb Company Profiles
Table 85. Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
Table 86. Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 87. Bristol-Myers Squibb Company Strategic initiatives
Table 88. Eli Lilly and Company Profiles
Table 89. Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
Table 90. Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 91. Eli Lilly and Company Strategic initiatives
Table 92. F. Hoffmann-La Roche Ltd. Profiles
Table 93. F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
Table 94. F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 95. F. Hoffmann-La Roche Ltd. Strategic initiatives
Table 97. Five Prime Therapeutics, Inc. Profiles
Table 98. Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
Table 99. Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 100. Five Prime Therapeutics, Inc. Strategic initiatives
Table 101. Genentech, Inc. Profiles
Table 102. Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
Table 103. Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 104. Genentech, Inc. Strategic initiatives
Table 105. Incyte Corporation Profiles
Table 106. Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
Table 107. Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 108. Incyte Corporation Strategic initiatives
Table 109. Johnson & Johnson Profiles
Table 110. Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
Table 111. Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 112. Johnson & Johnson Strategic initiatives
Table 113. MacroGenics, Inc. Profiles
Table 114. MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
Table 115. MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 116. MacroGenics, Inc. Strategic initiatives
Table 117. Novartis AG Profiles
Table 118. Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
Table 119. Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 120. Novartis AG Strategic initiatives
Table 121. Oncogenex Pharmaceuticals, Inc. Profiles
Table 122. Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
Table 123. Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 124. Oncogenex Pharmaceuticals, Inc. Strategic initiatives
Table 125. PsiOxus Therapeutics Limited Profiles
Table 126. PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
Table 127. PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 128. PsiOxus Therapeutics Limited Strategic initiatives
